Glenmark gets U.S. FDA warning letter for Indore plant
The U.S. Food and Drug Administration has issued a warning letter to Glenmark Pharmaceuticals for the company’s manufacturing facility in Indore, Madhya Pradesh. “The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility,” Glenmark said in a filing […]
Continue Reading
